Simin Baygani

927 total citations
37 papers, 629 citations indexed

About

Simin Baygani is a scholar working on Psychiatry and Mental health, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Simin Baygani has authored 37 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 8 papers in Surgery and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Simin Baygani's work include Migraine and Headache Studies (11 papers), Trigeminal Neuralgia and Treatments (7 papers) and Sexual function and dysfunction studies (6 papers). Simin Baygani is often cited by papers focused on Migraine and Headache Studies (11 papers), Trigeminal Neuralgia and Treatments (7 papers) and Sexual function and dysfunction studies (6 papers). Simin Baygani collaborates with scholars based in United States, United Kingdom and Japan. Simin Baygani's co-authors include Richard C. Bump, Harold P. Drutz, Linda Cardozo, Bruce J. Kinon, Sara Kollack‐Walker, David P. Walling, David H. Adams, Brian A. Millen, John H. Krege and Li Shen Loo and has published in prestigious journals such as Neurology, The Journal of Urology and The American Journal of Cardiology.

In The Last Decade

Simin Baygani

35 papers receiving 604 citations

Peers

Simin Baygani
Mike D. Smith United States
Kenneth Powers United States
Edoardo Ostardo Italy
Shigeo Kaneko Japan
Kristian Vinter Juul Denmark
Ediz Yeşilkaya Türkiye
Sebastian Schneider Germany
Karine Louati France
J. S. P. Lumley United Kingdom
Oscar Contreras Ortiz Argentina
Mike D. Smith United States
Simin Baygani
Citations per year, relative to Simin Baygani Simin Baygani (= 1×) peers Mike D. Smith

Countries citing papers authored by Simin Baygani

Since Specialization
Citations

This map shows the geographic impact of Simin Baygani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simin Baygani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simin Baygani more than expected).

Fields of papers citing papers by Simin Baygani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simin Baygani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simin Baygani. The network helps show where Simin Baygani may publish in the future.

Co-authorship network of co-authors of Simin Baygani

This figure shows the co-authorship network connecting the top 25 collaborators of Simin Baygani. A scholar is included among the top collaborators of Simin Baygani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simin Baygani. Simin Baygani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Panaccione, Remo, Simin Baygani, Deborah A. Fisher, et al.. (2025). Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis. Crohn s & Colitis 360. 7(2). otaf043–otaf043. 1 indexed citations
2.
Rubin, David T., Alison Potts Bleakman, Toshifumi Hibi∥, et al.. (2025). P0705 Features of optimal disease control in Crohn’s disease and Ulcerative Colitis: Views on IBD Expectations and Well-being by Patients and Treatment providers. Journal of Crohn s and Colitis. 19(Supplement_1). i1376–i1377. 1 indexed citations
3.
Clemow, David B., Marla C. Dubinsky, Simin Baygani, et al.. (2025). Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab. Journal of Patient-Reported Outcomes. 9(1). 75–75.
4.
Hart, Ailsa, et al.. (2024). OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis. Journal of Crohn s and Colitis. 18(Supplement_1). i27–i28. 3 indexed citations
5.
Laharie, David, Corey A. Siegel, Parambir S. Dulai, et al.. (2024). P932 Corticosteroid-sparing effect of mirikizumab for the treatment of moderately-to-severely active Ulcerative Colitis: Extended induction subgroup analysis from Phase 3 trial. Journal of Crohn s and Colitis. 18(Supplement_1). i1687–i1688. 1 indexed citations
6.
Krege, John H., Richard B. Lipton, Simin Baygani, et al.. (2022). Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis. Pain and Therapy. 11(2). 701–712. 10 indexed citations
7.
Rabe, Heike, Varsha Bhatt‐Mehta, Stephen Bremner, et al.. (2021). Antenatal and perinatal factors influencing neonatal blood pressure: a systematic review. Journal of Perinatology. 41(9). 2317–2329. 6 indexed citations
8.
Ahmed, Zubair, Vincent T. Martin, Andrew Buchanan, et al.. (2021). Tolerability of Lasmiditan in Elderly Patients with Migraine (1814). Neurology. 96(15_supplement).
9.
Vincent, Maurice, Mário Fernando Prieto Peres, Raghavendra Vasudeva, et al.. (2021). Lasmiditan Efficacy in Mild Versus Moderate or Severe Migraine Headaches (1811). Neurology. 96(15_supplement). 1 indexed citations
10.
Lipton, Richard B., Simin Baygani, Stewart J. Tepper, et al.. (2021). A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN. The Journal of Headache and Pain. 22(1). 101–101. 2 indexed citations
11.
Martin, Vincent T., Zubair Ahmed, Helen Hochstetler, et al.. (2021). Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies. Clinical Therapeutics. 43(6). 1066–1078. 13 indexed citations
12.
Clemow, David B., et al.. (2020). Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials. Current Medical Research and Opinion. 36(11). 1791–1806. 8 indexed citations
13.
Dionne, Janis M., Stephen Bremner, Simin Baygani, et al.. (2020). Method of Blood Pressure Measurement in Neonates and Infants: A Systematic Review and Analysis. The Journal of Pediatrics. 221. 23–31.e5. 55 indexed citations
14.
Loo, Li Shen, Jessica Ailani, Jack Schim, et al.. (2019). Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. The Journal of Headache and Pain. 20(1). 84–84. 30 indexed citations
15.
Davis, Jonathan M., Gerri Baer, Ronald J. Portman, et al.. (2017). Enrollment of Neonates in More Than One Clinical Trial. Clinical Therapeutics. 39(10). 1959–1969. 11 indexed citations
16.
17.
Goldfischer, Evan R., Edward D. Kim, Allen D. Seftel, Simin Baygani, & Patrick R. Burns. (2014). Impact of Low Testosterone on Response to Treatment With Tadalafil 5 mg Once Daily for Erectile Dysfunction. Urology. 83(6). 1326–1333. 9 indexed citations
18.
19.
Cardozo, Linda, Harold P. Drutz, Simin Baygani, & Richard C. Bump. (2004). Pharmacological Treatment of Women Awaiting Surgery for Stress Urinary Incontinence. Obstetrics and Gynecology. 104(3). 511–519. 84 indexed citations
20.
Wenger, Nanette K., Elizabeth Barrett‐Connor, Peter Collins, et al.. (2002). Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. The American Journal of Cardiology. 90(11). 1204–1210. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mike D. Smith Breakdown of academic impact, for papers by Kenneth Powers Breakdown of academic impact, for papers by Edoardo Ostardo Breakdown of academic impact, for papers by Shigeo Kaneko Breakdown of academic impact, for papers by Kristian Vinter Juul Breakdown of academic impact, for papers by Ediz Yeşilkaya Breakdown of academic impact, for papers by Sebastian Schneider Breakdown of academic impact, for papers by Karine Louati Breakdown of academic impact, for papers by J. S. P. Lumley Breakdown of academic impact, for papers by Oscar Contreras Ortiz
Rankless by CCL
2026